When GastroPanel is applied for the risk-screening of gastric cancer, concrete cost savings can be achieved based on the early diagnosis of gastritis and possibility to intervene before cancer develops:
- Fewer surgical and oncological treatments
- Reduce labour loss due to premature deaths
- First-line diagnosis of dyspeptic patients
- Less sick leave (caused by dyspepsia, ulcer etc.)
When GastroPanel is applied as a primary method for the screening of stomach troubles, patients can be directed to further measures that benefit them most. This includes: starting PPI medication, H. pylori eradication therapy and gastroscopy. With the help of these results, endoscopies can be done to those who truly benefit from it.
Biohit has developed a GastroPanel screening model calculation tool which can be used to demonstrate the level of savings (in EURO´s) achievable when GastroPanel screenings are used a primary investigation method for patients with stomach troubles, or, as a population-based screening program.
You may check and try out the screening and municipality models via following pages: